Tren-Capped Hexaphyrin Zinc Complexes : Interplaying Molecular Recognition, Möbius Aromaticity and Chirality

Hervé Ruffin, Gildas Nyame Mendendy Boussambe, Thierry Roisnel, Vincent Dorcet, Bernard Boitrel* and Stéphane Le Gac*

Institut des Sciences Chimiques de Rennes, UMR CNRS 6226, Université de Rennes 1, 263 avenue du Général Leclerc, 35042 Rennes cedex, France. bernard.boitrel@univ-rennes1.fr; stephane.legac@univ-rennes1.fr

SUPPORTING INFORMATION

Table of content

I. Experimental part

General	S3
Synthesis of 5-(2-nitrophenyl)dipyrromethane	S 3
Synthesis of 1	S4
Synthesis of 2	S4
Synthesis of 3	S5
Synthesis of 6	S 5
Synthesis of 4	S6
Synthesis of 5	S7
Synthesis of 9	S8
Synthesis of 10	S8
Synthesis of 8	S9
Synthesis of 11	S10
Metallation of 8 with Zn(II)	S11
Crystallographic data for 1	S14
Crystallographic data for 5	S14
Crystallographic data for 8Zn^{OAc}_{NH2Bu}.H⁺,OTf ⁻	S14
Dihedral angles (°) of 8Zn^{OAc}NH2Bu.H⁺,OTf ⁻ along the SMC	S15

II. NMR spectral data

Selected NMR spectra of 1	S16
Selected NMR spectra of 3 and 6	S18

Selected NMR spectra of 4	S19
Selected NMR spectra of 5	S21
Selected NMR spectra of 9	S23
Selected NMR spectra of 10	S24
Selected NMR spectra of 8	S26
Selected NMR spectra of 11	S28
Comparison of the ¹ H NMR spectra of 10 and 11	S30
Selected NMR spectra of 8Zn^{OAc}NH2Bu.H⁺,OTf ⁻ and 8Zn^{OAc}NH2Bu	S31

III. UV-vis-NIR absorption spectra

UV-vis-NIR absorption spectra of compounds 3 , 4 , 6 and 8	S41
UV-vis-NIR absorption spectra of compounds 5 and 10	S41
UV-vis-NIR absorption spectra for the titration of 8 by a 1:1 mixture of	
Zn(OAc) ₂ and BuNH ₂	S42
CD and UV-vis absorption spectra of (i) a solution of 8, Zn(OTf) ₂ and (R)-MBA	
vs. (ii) a solution of 8 , Zn(OTf) ₂ , (R)-MBA and TBAOAc	S43
Racemization study for the <i>M</i> <-> <i>P</i> twist interconversion in "8Zn"	S44

I. Experimental part

General

All chemicals were commercial products used as received. All reactions were conducted under inert atmosphere. Pyrrole was filtered through a plug of basic alumina before use. Anhydrous CH_2Cl_2 and THF were obtained, respectively, by distillation over CaH_2 and Na/benzophenone according to standard procedures. ¹H, ¹³C and ¹⁹F NMR spectra were recorded at 298 K (unless otherwise stated), at 500 MHz, 125 MHz and 376 MHz, respectively. Residual traces of solvent were used as internal standard. Chemical shifts are expressed in parts per million (ppm; s = singlet [s_b = broad singlet, and so on], d = doublet, t = triplet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, and br = broad signal) and coupling constants are given in Hz. The NMR experiments were conducted in 5 mm standard NMR tubes.

Synthesis of 5-(2-nitrophenyl)dipyrromethane¹



Under inert atmosphere, 2-nitrobenzaldehyde (25.0 g, 164 mmol) was solubilized in 275 mL of pyrrole (4.11 mol) and the mixture was degassed by argon bubbling during 15 min. TFA (1.3 mL, 16 mmol) was then added and the reaction was stirred at RT for 45 min. Upon addition of *ca*. 2 mL of Et₃N, pyrrole was removed under vacuum. The crude mixture was extracted with hexane from a CH_2Cl_2 solution and purified by silica gel column chromatography (eluent: CH_2Cl_2) to afford 5-(2-nitrophenyl)dipyrromethane as a reddish oil (35.4 g, 80%).

¹H NMR (CDCl₃, 298 K) δ 5.89 (s, 2H, c), 5.82 (d, J = 5.9 Hz, 2H, b), 6.21 (s, 1H, d), 6.73 (m, 2H, a), 7.28 (dd, J1 = 7.8 Hz, J2 = 1.3 Hz, 1H, h), 7.38 (td, J1 = 7.8 Hz, J2 = 1.3 Hz, 1H, g), 7.51 (td, J1 = 7.8 Hz, J2 = 1.3 Hz, 1H, f), 7.87 (dd, J1 = 7.8 Hz, J2 = 1.3 Hz, 1H, e), 8.16 (s, 2H, NH).

Synthesis of 1



Under inert atmosphere, at 0°C, MSA (440 μ L, 6.8 mmol) was added to a solution of 5-(2-nitrophenyl)dipyrromethane (30.0 g, 112 mmol) and pentafluorobenzaldehyde (22.0 g, 112 mmol) in CH₂Cl₂ (3.6 L). After 1h30, DDQ (76.3 g, 336 mmol) was added and the reaction was stirred at RT for an additional 2h. Et₃N (2 mL, 14 mmol) was added to stop the reaction and the solvent was removed under reduced pressure. The crude mixture was purified by silica gel column chromatography (eluent: CH₂Cl₂) to provide hexaphyrin **1** as a purple solid (6.4 g, 16 %).

¹H NMR (CDCl₃, 330 K, average spectrum) δ -2.36 (m, 4H, $\beta\pi_{in}$), -1.83 (m, 2H, NH), 7.95-8.20 (m, 8H, Ar), 8.39 (m, 1H, Ar_{d(S)}), 8.60 (m, 3H, Ar_{a(S+L)}), 8.86 (d, *J* = 4.7 Hz, 2H, $\beta\pi_1$), 8.99 (d, *J* = 4.7 Hz, 2H, $\beta\pi_4$), 9.26 (d, *J* = 4.7 Hz, 2H, $\beta\pi_2$), 9.33 (d, *J* = 4.8 Hz, 2H, $\beta\pi_3$). ¹⁹F NMR (CDCl₃, 298 K, complex spectrum corresponding to a mixture of atropisomers, see Figure S5) δ -164.35 (m, F_{meta}), -164.01 (m, F_{meta}), -162.99 (m, F_{meta}), -162.50 (m, F_{meta}), -161.26 (m, F_{meta}), -160.92 (m, F_{meta}), -160.54 (m, F_{meta}), -154.87 (m, F_{para}), -150.70 (t, J = 20.9 Hz, F_{para}), -138.52 (d, J = 24.2 Hz, F_{ortho}), -138.29 (d, J = 23.4 Hz, F_{ortho}), -137.62 (d, *J* = 24.4 Hz, F_{ortho}), -137.28 (d, *J* = 24.4 Hz, F_{ortho}), -137.01 (d, *J* = 24.7 Hz, F_{ortho}), -136.80 (m, F_{ortho}), -136.64 (d, *J* = 24.4 Hz, F_{ortho}), -136.21 (m, F_{ortho}), -136.07 (d, *J* = 26.4 Hz, F_{ortho}), -135.76 (d, *J* = 24.1 Hz, F_{ortho}), -135.58 (d, *J* = 24.0 Hz, F_{ortho}). UV-visible (CHCl₃, λ_{max} nm/ε L·mol⁻¹·cm⁻¹): 566 (141149), 600 (51758), 714 (18735), 744 (8639), 901 (7728), 1024 (11970). HRMS (ESI-TOF, positive ion mode): *m*/z calcd for C₆₆H₂₇N₉O₆F₁₅: 1326.1844 [M+H⁺]; found 1326.1854.

Synthesis of 2



In a sealed reactor, Pd(0)/C (30 wt. % loading, 12.5 mg) was added to hexaphyrin **1** (250 mg, 190 μ mol) in AcOEt (20 mL). The reaction was stirred under a pressure of H₂ (80 bar) for 24 h at 30 °C, then filtered through a plug of celite. AcOEt was removed under reduced pressure affording **2** as the major compound. The crude mixture was used in the next steps without purification.

Synthesis of 3



Under inert atmosphere, the crude hexaphyrin **2**, obtained from 250 mg of **1**, was solubilized in anhydrous THF (10 mL) and, at -50°C, DIPEA (164 μ L, 940 μ mol) and acryloyl chloride (55 μ L, 670 μ mol) were added. After 30 min of stirring, the excess of acyl chloride was quenched by addition of of MeOH (1 mL). THF was removed under reduced pressure and the residue was purified by silica gel column chromatography (eluent: CH₂Cl₂/AcOEt 97:3) to afford hexaphyrin **3** as a blue solid (109 mg, 41 % overall yield from **1**).

¹H NMR (CDCl₃, 298 K): broad spectrum due to fast equilibrium between Möbius conformers (see text and Figure S6a). UV-visible (CHCl₃, λ_{max} nm): 393, 446, 604, 774, 866, 913, 1022. HRMS (ESI-TOF, positive ion mode): *m/z* calcd for C₇₅H₄₁N₉O₃F₁₅: 1400.3093 [M+H⁺]; found 1400.3086.

Synthesis of 6



Under inert atmosphere, the crude hexaphyrin **2**, obtained from 250 mg of **1**, was solubilized in anhydrous THF (10 mL) and, at 0°C, Et₃N (128 μ L, 912 μ mol) and 3-(chloromethyl)benzoyl chloride (97 μ L, 682 μ mol) were successively added. After 30 min of stirring, the excess of acyl chloride was quenched by addition of butylamine (75 μ L, 760 μ mol). THF was removed under reduced pressure and the residue was purified by silica gel column chromatography (eluent: CH₂Cl₂) to afford hexaphyrin **6** as a blue solid (150 mg, 46 % overall yield from **1**).

¹H NMR (CDCl₃, 298 K): broad spectrum due to fast equilibrium between Möbius conformers (see text and Figure S6b). UV-visible (CHCl₃, λ_{max} nm/ ϵ L·mol⁻¹·cm⁻¹): 398 (30237), 454 (29580), 604 (174408), 633 (88085), 774 (13620), 865 (8400), 913 (7527), 1036 (3807). HRMS (ESI-TOF, positive ion mode): *m/z* calcd for C₉₀H₅₀N₉O₃F₁₅³⁵Cl₃: 1694.2857 [M+H⁺]; found 1694.2852.

Synthesis of 4



Under inert atmosphere, a solution of hexaphyrin **3** (51 mg, 36 µmol) and tris(2-aminoethyl)amine (5.4 µL, 36 µmol) in MeOH/CHCl₃ (9:1, 50 mL) was stirred overnight at 45°C. The solvents were then removed under reduced pressure and the residue was purified by silica gel column chromatography (eluent: $CH_2Cl_2/MeOH$ 90:10, with 5 % v:v of Et_3N), then washed twice with water to afford hexaphyrin **4** as a reddish solid (23 mg, 41 %).

¹H NMR (CDCl₃, 298 K) δ 2.40 (s_b, 2H, NH_{out}) 2.73 (m, 2H, CH_{2e(S)}), 2.91 (m, 2H, CH_{2e(L)}), 3.16 (d, J = 4.6 Hz, 2H, βπ_{out}), 3.36 (m, 6H, βπ_{out}), 3.49 (m, 2H, CH_{2e(L})), 3.68 (m, 2H, CH_{2f(S})), 3.95 (m, 2H, CH_{2f(L})), 4.17 (m, 2H, CH_{2f(L)}), 5.29 (m, 2H, CH_{2e(L)}), 5.53 (m, 2H, CH_{2e(S})), 5.89 (m, 2H, CH_{2e(L})), 6.07 (d, J = 7.8 Hz, 2H, Hz, 2H, $Ar_{c(L)}$), 6.76 (t, J = 7.6 Hz, 2H, $Ar_{b(L)}$), 6.86 (m, 2H, $CH_{2h(L)}$), 6.87 (t, J = 7.6 Hz, 1H, $Ar_{b(S)}$), 6.98 (m, 2H, CH_{2h(L)}), 7.08 (d, J = 7.7 Hz, 2H, Ar_{a(L)}), 7.77 (d, J = 8.0 Hz, 1H, Ar_{a(S)}), 8.36 (s, 2H, CONH_(L)), 11.19 (s, 1H, CONH_(S)), 19.93 (s_b, 2H, βπ_{in}), 20.52 (s_b, 2H, βπ_{in}), 26.79 (s_b, 2H, NH_{in}). ¹⁹F NMR (CDCl₃, 298 K) δ -160.72 (dt, J1 = 21.8 Hz, J2 = 8.1 Hz, 1F, $F_{m(S)}$), -160.58 (m, 3F, $F_{m(S+L)}$), -159.44 (dt, J1 = 22.7 Hz, J2 = 8.1 Hz, 2F, $F_{m(L)}$), -154.73 (t, J = 21.0 Hz, 1F, $F_{p(S)}$), -153.03 (t, J = 21.1 Hz, 2F, $F_{p(L)}$), -139.82 (d, J = 23.6 Hz, 2F, $F_{o(L)}$, -139.55 (dd, J1 = 24.8, J2 = 8.3 Hz, 1F, $F_{o(S)}$), -139.34 (dd, J1 = 24.6, J2 = 8.5 Hz, 1F, $F_{o(S)}$), -138.55 (d, J = 21.6 Hz, 2F, $F_{o(L)}$). Partial ¹³C from 2D HSQC (CDCl₃, 298 K) δ 35.3 (1C, $C_{e(S)}$), 36.6 (2C, C_{e(L)}), 45.4 (2C, C_{f(L)}), 46.3 (1C, C_{f(S)}), 47.2 (2C, C_{g(L)}), 48.6 (1C, C_{g(S)}), 54.7 (2C, C_{h(L)}), 57.3 (1C, C_{h(S)}), 122.3 (1C, C_{a(S)}), 123.5 (2C, C_{βπin}), 123.9 (1C, C_{c(S)}), 124.9 (2C, C_{βπin}), 125.2 (2C, C_{a(L)}), 125.8 (2C, C_{c(L)}), 126.1 (2C, C_{βπout}), 128.4 (1C, C_{b(5)}), 128.5 (2C, C_{βπout}), 128.9 (2C, C_{d(L})), 129.0 (2C, C_{b(L})), 129.1 (1C, C_{d(5)}), 130.5 (2C, $C_{\beta\pi out}$), 132.4 (2C, $C_{\beta\pi out}$). UV-visible (CHCl₃, λ_{max} nm/ ϵ L·mol⁻¹·cm⁻¹): 426 (39220), 488 (105568), 526 (61807), 577 (66258), 608 (47290). HRMS (ESI-TOF, positive ion mode): m/z calcd for C₈₁H₅₉N₁₃O₃F₁₅: 1546.4618 [M+H⁺]; found 1546.4616.

Synthesis of 5



Under inert atmosphere, a solution of hexaphyrin **3** (60 mg, 42 μ mol) and tris[2-(methylamino)ethyl]amine (9 μ L, 43 μ mol) in MeOH/CHCl₃ (9:1, 60 mL) was stirred overnight at 45°C. The solvents were removed under reduced pressure and the residue was purified by silica gel column chromatography (eluent: CH₂Cl₂/MeOH 90:10, with 1 % v:v of Et₃N), then washed twice with water to afford hexaphyrin **5** as a reddish solid (46 mg, 67 %).

¹H NMR (CDCl₃, 298 K) δ 3.08 (m, 4H, CH_{2e(L)}), 3.15 (d, J = 5.1 Hz, 2H, $\beta \pi_{out}$), 3.21 (m, 4H, $\beta \pi_{out}$), 3.27 (m, 2H, CH_{2e(5)}), 3.39 (d, J = 5.3 Hz, 2H, $\beta \pi_{out}$), 3.73 (s, 3H, CH₃₍₅₎), 3.81 (m, 4H, CH_{2f(L})), 4.16 (m, 2H, $CH_{2f(5)}$, 4.97 (s, 6H, $CH_{3(L)}$), 5.82 (m, 6H, $CH_{2h(5+L)+g(L)}$), 5.95 (m, 3H, $Ar_{d(5)} + CH_{2h(L)}$), 6.20 (d, J = 7.7 Hz, 2H, $Ar_{d(L)}$), 6.53 (t, J = 6.8 Hz, 2H, $Ar_{c(L)}$), 6.57 (t, J = 7.8 Hz, 1H, $Ar_{c(S)}$), 6.75 (t, J = 7.2, 2H, $Ar_{b(L)}$), 6.86 (t, J = 7.6 Hz, 1H, $Ar_{b(S)}$), 7.01 (m, 2H, $CH_{2g(L)}$), 7.52 (d, J = 8.1 Hz, 2H, $Ar_{a(L)}$), 7.94 (d, J = 8.1 Hz, 1H, $Ar_{a(S)}$), 8.49 (m_b, 2H, CH_{2g(5)}), 8.97 (s, 2H, CONH_(L)), 11.07 (s, 1H, CONH_(S)), 20.37 (s_b, 2H, βπ_{in}), 20.53 (s_b, 2H, $\beta \pi_{in}$), 27.07 (s_b, 2H, NH_{in}). ¹⁹F NMR (CDCl₃, 298 K) δ -160.74 (dt, J1 = 20.5 Hz, J2 = 9.9 Hz, 1F, F_{m(S)}), -160.34 (dt, J1 = 20.9 Hz, J2 = 8.3 Hz, 1F, $F_{m(S)}$), -159.74 (m, 2F, $F_{m(L)}$), -158.28 (m, 2F, $F_{m(L)}$), -154.58 (t, J = 21.2 Hz, 1F, $F_{\rho(S)}$), -152.25 (t, J = 20.9 Hz, 2F, $F_{\rho(L)}$), -140.15 (dd, J1 = 24.3 Hz, J2 = 8.3 Hz, 1F, $F_{o(S)}$), -139.52 (dd, J1 = 24.4, J2 = 8.5 Hz, 1F, $F_{o(S)}$), -139.14 (d, J = 23.9 Hz, 2F, $F_{o(L)}$), -138.16 (d, J = 23.6 Hz, 2F, F_{o(L)}). Partial ¹³C from 2D HSQC (CDCl₃, 298 K) δ 34.5 (1C, C_{e(S)}), 34.9 (2C, C_{e(L)}), 41.2 (1C, NMe_(S)), 43.5 $(2C, NMe_{(L)}), 51.7 (1C, C_{h(S)}), 53.0 (1C, C_{f(S)}), 54.0 (2C, C_{h(L)}), 54.1 (2C, C_{f(L)}), 57.7 (2C, C_{g(L)}), 59.9 (1C, C_{h(L)}), 59.9 (1C, C$ Cg(S), 121.6 (2C, Ca(L)), 122.4 (1C, Ca(S)), 124.4 (2C, Cc(L)), 124.6 (4C, Cβπin), 124.7 (1C, Cc(S)), 126.0 (2C, C_{βπout}), 128.6 (1C, C_{b(S)}), 128.7 (2C, C_{βπout}), 129.0 (2C, C_{d(L)}), 129.3 (2C, C_{b(L)}), 129.6 (1C, C_{d(S)}), 130.4 (2C, $C_{\beta\pi out}$), 132.9 (2C, $C_{\beta\pi out}$). UV-visible (CHCl₃, λ_{max} nm/ ϵ L·mol⁻¹·cm⁻¹): 484 (114279), 528 (56238), 578 (63088). HRMS (ESI-TOF, positive ion mode): m/z calcd for C₈₄H₆₅N₁₃O₃F₁₅: 1588.5088 [M+H⁺]; found 1588.5087.

Synthesis of 9

Note: compound **9** could not be isolated with high purity due to tedious purification, and was thus formed by addition of DDQ to an NMR tube solution of **4** for spectroscopic characterization.



In a NMR tube, hexaphyrin **4** (3 mg, 1.9 μ mol) was dissolved in 500 μ L of 9:1 CDCl₃/CD₃OD. At 25 °C DDQ (0.5 mg, 2.2 μ mol) was added to this solution. After 30 min, Et₃N (16 μ L) was added. ¹H NMR spectrum showed quasi-quantitative formation of **9**. Note: an excess of both CD₃OD and Et₃N was needed to obtain a well resolved NMR spectrum.

¹H NMR (9:1 CDCl₃/CD₃OD, 298 K) δ -3.10 (4H, d_b, $\beta \pi_{in}$), -2.02 (m, 2H, CH_{2g/h}) -1.51 (m, 2H, CH_{2g/h}), -1.37 (m, 2H, CH_{2g/h}), -1.20 (m, 2H, CH_{2g/h}), -1.08 (m, 2H, CH_{2g/h}), -1.02 (m, 2H, CH_{2g/h}), 0.11 (m, 2H, CH_{2e/f}), 0.91 (m, 2H, CH_{2e/f}), 1.05 (m, 2H, CH_{2e/f}), 1.35 (m, 2H, CH_{2e/f}), 1.54 (m, 2H, CH_{2e/f}), 1.71 (m, 2H, CH_{2e/f}), 7.65 (t, J = 6.7 Hz, 1H, Ar_{c(S)}), 7.75 (m, 2H, Ar_{c(L)}), 7.93 (m, 4H, Ar_{b(L+S)}), 8.22 (d, J = 8.4 Hz, 2H, Ar_{a(L)}), 8.30 (m, 1H, Ar_{d(S)}), 8.41 (m, 2H, Ar_{d(L)}), 8.72 (d, J = 8.8 Hz, 1H, Ar_{a(S)}), 9.09 (m, 2H, $\beta \pi_{out}$), 9.23 (m, 2H, $\beta \pi_{out}$), 9.47 (m, 2H, $\beta \pi_{out}$), 9.51 (m, 2H, $\beta \pi_{out}$). Partial ¹³C from 2D HSQC (9:1 CDCl₃/CD₃OD, 298 K) δ 121.8 (2C, C_{βπin}), 122.5 (1C, C_{a(S)}), 122.8 (2C, C_{βπin}), 123.7 (1C, C_{c(S)}), 124.6 (2C, C_{c(L)}), 124.9 (2C, C_{a(L)}), 129.9 (2C, C_{b(L)}), 130.5 (1C, C_{b(S)}), 131.7 (2C, C_{βπout}), 134.1 (2C, C_{βπout}), 134.4 (2C, C_{βπout}), 135.0 (1C, C_{d(S)}), 135.4 (2C, C_{d(L)}), 136.4 (2C, C_{βπout}).

Synthesis of 10



DDQ (4.8 mg, 21.1 μ mol) was added to a solution of hexaphyrin **5** (17 mg, 10.7 μ mol) in CHCl₃ (2 mL). After stirring for 10 min at room temperature, Et₃N (100 μ L) was added. CHCl₃ was removed under

reduced pressure and the crude product was purified by silica gel column chromatography (eluent: $CH_2Cl_2/MeOH$ 90:10, with 1 % v/v of Et_3N) to afford hexaphyrin **10** as a purple solid (14 mg, 82 %).

¹H NMR (CDCl₃, 298 K) δ -3.18 (d, J = 3.8 Hz, 2H, $\beta \pi_{in}$), -3.05 (d, J = 3.8 Hz, 2H, $\beta \pi_{in}$), -2.85 (m, 2H, CH_{2g/h(S)}), -2.46 (m, 2H, CH_{2g/h(L)}), -1.25 (m, 4H, CH_{2g/h(L)}), -1.01 (m, 2H, CH_{2g/h(L)}), -0.77 (m, 2H, CH_{2g/h(S)}), -0.47 (s, 6H, CH_{3(L)}), 0.49 (s, 3H, CH_{3(S)}), 0.74 (m, 2H, CH_{2e/f(S)}), 1.15 (m, 2H, CH_{2e/f(L)}), 1.19 (m, 2H, CH_{2e/f(S)}), 1.39 (m, 2H, CH_{2e/f(L)}), 1.69 (m, 2H, CH_{2e/f(L)}), 1.79 (m, 2H, CH_{2e/f(L)}), 7.69 (t, J = 7.7 Hz, 1H, $Ar_{c(S)}$, 7.72 (t, J = 7.5 Hz, 2H, $Ar_{c(L)}$), 7.97 (t, J = 7.8 Hz, 1H, $Ar_{b(S)}$), 8.00 (t, J = 8.0 Hz, 2H, $Ar_{b(L)}$), 8.16 (d, J = 7.3 Hz, 2H, Ar_{d(L)}), 8.38 (d, J = 8.4 Hz, 1H, Ar_{d(S)}), 8.50 (d, J = 8.4 Hz, 2H, Ar_{a(L)}), 8.78 (d, J = 8.8 Hz, 1H, Ar_{a(S)}), 9.10 (d, J = 4.7 Hz, 2H, $\beta \pi_{out}$), 9.30 (d, J = 4.7 Hz, 2H, $\beta \pi_{out}$), 9.37 (s, 2H, NHCO_(L)), 9.53 (d, J = 4.7 Hz, 2H, $\beta \pi_{out}$), 9.10 (d, J = 4.7 Hz, Hz, 2H, β π_{out}), 9.61 (d, J = 4.8 Hz, 2H, β π_{out}), 9.82 (s, 1H, NHCO₍₅₎). ¹⁹F NMR (CDCl₃, 298 K) δ -163.20 (td, J1 = 23.1 Hz, J2 = 7.8 Hz, 2F, $F_{m(L)}$), -162.32 (td, J1 = 22.0 Hz, J2 = 7.2 Hz, 2F, $F_{m(L)}$), -160.77 (m, 2F, $F_{m(5)}$, -153.14 (t, J = 20.8 Hz, 2F, $F_{p(L)}$), -150.24 (t, J = 20.7 Hz, 1F, $F_{p(5)}$), -139.21 (d, J = 23.5 Hz, 2F, $F_{o(L)}$), -137.51 (d, J = 23.3 Hz, 2F, $F_{o(L)}$), -136.76 (dd, J1 = 24.9 Hz, J2 = 8.1 Hz, 1F, $F_{o(S)}$), -136.46 (dd, J1 = 27.1 Hz, J2 = 8.4 Hz, 1F, $F_{o(5)}$). Partial ¹³C from 2D HSQC (CDCl₃, 298 K) δ 32.8 (1C, $C_{e/f(5)}$), 33.0 (2C, $C_{e/f(L)}$), 37.0 (1C, NMe_(S)), 37.6 (2C, NMe_(L)), 43.0 (1C, C_{g/h(S)}), 46.7 (2C, C_{g/h(L)}), 49.2 (1C, C_{e/f(S)}), 50.9 (1C, C_{g/h(S)}), 51.0 (2C, $C_{e/f(L)}$), 51.6 (2C, $C_{g/h(L)}$), 122.4 (2C, $C_{\beta\pi in}$), 122.5 (2C, $C_{\beta\pi in}$), 122.9 (1C, $C_{a(S)}$), 123.4 (1C, $C_{c(S)}$), 124.2 (2C, C_a(L)), 124.6 (2C, C_c(L)), 129.9 (2C, C_b(L)), 131.0 (1C, C_b(S)), 131.6 (2C, C_{βπout}), 134.0 (2C, C_{βπout}), 134.3 (2C, C_{βπout}), 135.3 (1C, C_{d(S)}), 135.9 (2C, C_{d(L})), 137.3 (2C, C_{βπout}). UV-visible (CHCl₃, λ_{max} nm/ε L·mol⁻¹·cm⁻¹): 488 (49153), 570 (160870), 581 (175624), 607 (68791), 718 (16335), 779 (3917), 904 (6035), 1028 (13156). HRMS (ESI-TOF, positive ion mode): *m*/*z* calcd for C₈₄H₆₃N₁₃O₃F₁₅: 1586.4931 [M+H⁺]; found 1586.4931.

Synthesis of 8



Under inert atmosphere, sodium iodide (51 mg, 340 μ mol) and DIPEA (57 μ L, 340 μ mol) were successively added to a solution of **6** (57 mg, 34 μ mol) in anhydrous THF (60 mL) and the mixture was refluxed for 4 hours. Tris[2-(methylamino)ethyl]amine (7 μ L, 34 μ mol) was then added and the reaction was stirred at 50 °C overnight. THF was removed under reduced pressure and the residue was purified by silica gel column chromatography (eluent: CH₂Cl₂/MeOH 90:10, with 2 % v/v of Et₃N) affording, after washing with water, hexaphyrin **8** as a reddish solid (33 mg, 55 %).

¹H NMR (CDCl₃, 298 K) δ 2.80 (s_b, 2H, NH_{out}), 3.03 (s, 3H, CH₃₍₅₎), 3.45 (m, 2H, $\beta \pi_{out}$), 3.47 (s, 6H, CH_{3(L)}), 3.55 (d_b, J = 4.6 Hz, 2H, $\beta \pi_{out}$), 3.59 (d, J = 4.7 Hz, 2H, $\beta \pi_{out}$), 3.68 (d, J = 4.9 Hz, 2H, $\beta \pi_{out}$), 3.75-3.85

(m, 10H, $CH_{2i/k}$), 4.01 (m, 2H, $CH_{2i/k}$), 4.43 (s, 2H, $CH_{2i(5)}$), 4.73 (d, J = 13.6 Hz, 2H, $CH_{2i(L)}$), 4.78 (d, J = 13.6 Hz, 2H, $CH_{2i(L)}$), 6.38 (d, J = 7.2 Hz, 3H, $Ar_{d(S+L)}$), 6.70 (t, J = 7.2 Hz, 2H, $Ar_{c(L)}$), 6.71 (t, J = 7.2 Hz, 1H, Ar_{c(S)}), 6.87 (t, J = 7.1 Hz, 2H, Ar_{b(L)}), 6.97 (t, J = 7.4 Hz, 1H, Ar_{b(S)}), 7.16 (s, 2H, NHCO_(L)), 7.47 (d, J = 7.9 Hz, 2H, Ar_{a(L)}), 7.77 (t, J = 7.5 Hz, 1H, Ar_{B(S)}), 7.84 (d, J = 7.7 Hz, 1H, Ar_{h(S)}), 7.91 (s, 1H, NHCO_(S)), 8.03 (d, J = 7.7 Hz, 1H, $Ar_{a(5)}$), 8.04 (d, J = 7.8 Hz, 1H, $Ar_{f(5)}$), 8.14 (d, J = 7.4 Hz, 2H, $Ar_{h(L)}$), 8.21 (t, J = 7.5 Hz, 2H, $Ar_{g(L)}$), 8.30 (s, 1H, $Ar_{e(S)}$), 8.37 (d, J = 7.5 Hz, 2H, $Ar_{f(L)}$), 8.45 (s, 2H, $Ar_{e(L)}$), 19.01 (s_b, 2H, $\beta\pi_{in}$), 19.14 (s_b, 2H, $\beta\pi_{in$ 2H, β π_{in}), 25.73 (m, 2H, NH_{in}). ¹⁹F NMR (CDCl₃, 298 K) δ -160.62 (m, 4F, F_m), -158.79 (t_b, J = 22.3 Hz, 2F, F_m), -154.50 (t, J = 21.7 Hz, 1F, $F_{p(S)}$), -152.79 (t, J = 22.1 Hz, 2F, $F_{p(L)}$), -139.77 (dd, J1 = 24.6 Hz, J2 = 8.4 Hz, 1F, $F_{o(S)}$), -139.06 (dd, J1 = 24.4, J2 = 8.6 Hz, 1F, $F_{o(S)}$), -138.52 (d, J = 21.9 Hz, 2F, $F_{o(L)}$), -137.32 (d, J = 23.8 Hz, 2F, $F_{o(L)}$). Partial ¹³C from 2D HSQC (CDCl₃, 298 K) δ 44.2 (1C, NMe_(S)), 45.1 (2C, NMe_(L)), 55.3-56.8 (6C, C_{j/k}), 64.0 (3C, C_i), 121.3 (1C, C_{a(5)}), 123.2 (2C, C_{a(L})), 123.9 (2C, C_{βπin}), 124.2 (2C, C_{βπin}), 125.5 (3C, $C_{c(S+L)}$), 126.6 (2C, $C_{\beta\pi out}$), 126.7 (2C, $C_{h(L)}$), 126.9 (1C, $C_{h(S)}$), 128.3 (1C, $C_{e(S)}$), 128.6 (2C, C_{βπout}), 129.3 (3C, C_{b(S)+e(L)}), 129.7 (5C, C_{b(L)+d(S+L)}), 130.1 (3C, C_{g(S+L)}), 131.2 (2C, C_{βπout}), 132.3 (2C, C_{βπout}), 133.6 (1C, C_{f(S)}), 134.2 (2C, C_{f(L)}). UV-visible (CHCl₃, λ_{max} nm/ε L·mol⁻¹·cm⁻¹): 410 (23768), 439 (44683), 488 (93368), 579 (76945), 606 (57401). HRMS (ESI-TOF, positive ion mode): m/z calcd for C₉₉H₇₁N₁₃O₃F₁₅: 1774.5563 [M+H⁺]; found 1774.5541.

Synthesis of 11

Note: compound **11** could not be isolated with high purity due to tedious purification, and was thus formed by addition of DDQ to an NMR tube solution of **8** for spectroscopic characterization.



In a NMR tube, hexaphyrin **8** (10 mg, 5.6 μ mol) was dissolved in 500 μ L of CDCl₃. At 25 °C, DDQ (1.5 mg, 6.6 μ mol) was added to this solution. After 30 min, Et₃N (16 μ L) was added. ¹H NMR spectrum showed quasi-quantitative formation of **11**. Note: a large excess of Et₃N was needed to obtain a well resolved NMR spectrum.

¹H NMR (CDCl₃, 298 K) δ -2.99 (d_b, J = 4.1 Hz, 2H, $\beta\pi_{in}$), -2.96 (d_b, J = 4.1 Hz, 2H, $\beta\pi_{in}$), 0.07 (m, 2H, CH_{2j/k(L)}), 0.17 (m, 2H, CH_{2j/k(L)}), 0.21 (s, 6H, CH_{3(L)}), 0.41 (m, 4H, CH_{2j/k(L)}), 0.63 (m, 2H, CH_{2j/k(S)}), 0.87 (m, 2H, CH_{2j/k(S)}), 1.20 (s, 3H, CH_{3(S)}), 1.51 (d, J = 12.0 Hz, 2H, CH_{i(L})), 1.83 (m, 2H, CH_{i(L})), 2.55 (s, 2H, CH_{i(S)}), 5.94 (s, 2H, Ar_{e(L})), 6.52 (m, 5H, Ar_{g(L)+f(L)+e(S)}), 6.66 (t, J = 7.5 Hz, 1H, Ar_{g(S)}), 6.81 (d, J = 7.5 Hz, 1H, Ar_{f(S)}), 7.05 (m, 3H, Ar_{h(S+L)}), 7.66 (t, J = 8.5 Hz, 2H, Ar_{c(L)}), 7.69 (s, 1H, NHCO_(S)), 7.77 (t, J = 7.6 Hz, 1H, Ar_{c(S)}), 7.90 (d, J = 7.4 Hz, 2H, Ar_{d(L})), 8.01 (t, J = 8.5 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, 2H, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (d, J = 7.3 Hz, Ar_{b(L)}), 8.04 (t, J = 7.6 Hz, 1H, Ar_{b(S)}), 8.35 (t, J =

Hz, 1H, Ar_{d(S)}), 8.61 (d, J = 8.4 Hz, 2H, Ar_{a(L)}), 8.73 (d, J = 7.7 Hz, 1H, Ar_{a(S)}), 9.08 (d, J = 4.2 Hz, 2H, $\beta\pi_{out}$), 9.23 (s, 2H, NHCO_(L)), 9.37 (d, J = 4.2 Hz, 2H, $\beta\pi_{out}$), 9.54 (d, J = 4.2 Hz, 2H, $\beta\pi_{out}$), 9.58 (d, J = 4.2 Hz, 2H, $\beta\pi_{out}$). Partial ¹³C from 2D HSQC (CDCl₃, 298 K) δ 41.6 (2C, NMe_(L)), 42.8 (1C, NMe_(S)), 51.2 (2C, C_{j/k(L)}), 51.7 (1C, C_{j/k(S)}), 53.0 (3C, C_{j/k(L+S)}), 61.3 (2C, C_{i(L)}), 62.1 (1C, C_{i(S)}), 121.8 (2C, C_{βπin}), 123.1 (2C, C_{βπin}), 123.4 (1C, C_{a(S)}), 124.5 (2C, C_{a(L)}), 124.7 (1C, C_{c(S)}), 124.9 (2C, C_{c(L)}), 125.9 (2C, C_{e(L)}), 126.2 (3C, C_{h(S+L)}), 126.7 (1C, C_{e(S)}), 128.4 (2C, C_{f/g(L)}), 128.8 (1C, C_{g(S)}), 130.3 (2C, C_{b(L)}), 131.2 (1C, C_{b(S)}), 131.5 (2C, C_{f/g(L)}), 131.8 (2C, C_{βπout}), 132.4 (1C, C_{f(S)}), 134.1 (2C, C_{βπout}), 134.6 (2C, C_{βπout}), 136.4 (1C, C_{d(S)}), 136.9 (2C, C_{d(L)}), 137.4 (2C, C_{βπout}). HRMS (ESI-TOF, positive ion mode): *m/z* calcd for C₉₉H₆₉N₁₃O₃F₁₅: 1772.5406 [M+H⁺]; found 1772.5393.

Metallation of 8 with Zn(II)

• General procedures, pathway A and B:

Pathway A. The three following solutions were prepared:

- **S1**: 12.3 mg of Zn(OTf)₂ in 9:1 CDCl₃/CD₃OD (500 μL).
- **S2**: 10.5 mg of Bu₄NOAc in 9:1 CDCl₃/CD₃OD (500 μL).
- **S3**: 3.4 μ L of butylamine in 9:1 CDCl₃/CD₃OD (500 μ L).

In a NMR tube, hexaphyrin **8** (4.8 mg, 2.7 μ mol) was dissolved in 9:1 CDCl₃/CD₃OD (500 μ L). To this solution, 40 μ L of S1 (1 equiv.), 40 μ L of S2 (1 equiv.) and 40 μ L of S3 (1 equiv.) were successively added at room temperature. A ¹H NMR spectrum recorded at 298 K showed quasi-quantitative formation of **8Zn^{OAc}_{NH2Bu}.H⁺,OTf**.

Pathway B. The following solution was prepared:

- **S4**: 7.4 mg of Zn(OAc)₂ in 9:1 CDCl₃/CD₃OD (500 μL).

In a NMR tube, hexaphyrin **8** (4.8 mg, 2.7 μ mol) was dissolved in 9:1 CDCl₃/CD₃OD (500 μ L). To this solution, 1 μ L (3 equiv.) of butylamine, 3.5 μ L (7 equiv.) of DIPEA and 140 μ L (3.5 equiv.) of S4 were added at room temperature. A ¹H NMR spectrum recorded at 298 K showed quasi-quantitative formation of **8Zn**^{OAc}_{NH2Bu}.

NMR description of 8Zn^{OAc}_{NH2Bu}[.H⁺,OTf⁻], pathway A vs. B (partial descriptions because of a strong overlapping and/or highly broaden signals [e.g. CH₂ tren protons])

Pathway A:



¹H NMR (9:1 CDCl₃/CD₃OD, 298 K) δ -3.50 (d, J = 4.3 Hz, 1H, $\beta\pi^2$), -2.21 (s, 3H, CH_{30AC}), -1.72 (d, J = 4.4 Hz, 1H, $\beta\pi^2$), 1.28 (m, 1H, Ar6b), 1.96 (m, 1H, ArCH₂), 2.30 (d, J = 11.4 Hz, 1H, ArCH₂), 2.44 (d, J = 12.6 Hz, 1H, ArCH₂), 2.69 (d, J = 12.6 Hz, 1H, ArCH₂), 3.07 (m, 1H, Ar6c), 3.41 (m, 1H, Ar6d), 3.57 (d, J = 12.8 Hz, 1H, ArCH₂), 4.27 (m, 1H, ArCH₂), 4.37 (d, J = 3.9 Hz, 1H, $\beta\pi^5$), 4.59 (d, J = 4.6 Hz, 1H, $\beta\pi^5$), 6.52 (s, 1H, Ar6a), 6.54 (d, J = 7.8 Hz, 1H, ArCH₂), 4.37 (d, J = 3.9 Hz, 1H, $\beta\pi^5$), 4.59 (d, J = 4.6 Hz, 1H, $\beta\pi^5$), 6.52 (s, 1H, Ar6a), 6.54 (d, J = 7.8 Hz, 1H, Arrmeso), 6.64 (s, 1H, Artren), 6.85 (d, J = 7.8 Hz, 1H, Artren), 6.97 (t, J = 7.9 Hz, 1H, Armeso), 7.01 (t, J = 7.5 Hz, 1H, Artren), 7.09 (d, J = 4.7 Hz, 1H, $\beta\pi_{out}$), 7.12 (d, J = 7.4 Hz, 1H, Armeso), 7.19 (d, J = 5.1 Hz, 1H, $\beta\pi_{out}$), 7.24 (t, J = 8.2 Hz, 1H, Armeso), 7.37 (t, J = 7.7 Hz, 1H, Armeso), 7.43 (m, 2H, Artren+ $\beta\pi_{out}$), 7.60 (m, 3H, Armeso+2Artren), 7.69 (t, J = 7.9 Hz, 1H, Armeso), 7.72 (t, J = 7.9 Hz, 1H, Armeso), 7.78 (d, J = 7.9 Hz, 1H, Armeso), 7.88 (d, J = 4.8 Hz, 1H, $\beta\pi_{out}$), 7.99 (d, J = 4.3 Hz, 1H, $\beta\pi_{out}$), 8.06 (s, 1H, Artren), 8.13 (m, 2H, Artren+ $\beta\pi_{out}$), 8.23 (d, J = 8.5 Hz, 1H, Armeso), 8.29 (m, 2H, Armeso+ $\beta\pi_{out}$), 8.43 (d, J = 4.3 Hz, 1H, $\beta\pi_{out}$), 8.56 (d, J = 8.6 Hz, 1H, Armeso). ¹⁹F NMR (9:1 CDCl₃/CD₃OD, 298 K) δ -162.70 (dt, J1 = 22.9 Hz, J2 = 8.1 Hz, 1F, F_m), -162.29 (m, 3F, F_o), -160.78 (m, 2F, F_o), -154.23 (t, J = 20.9 Hz, 1F, F_p), -154.19 (t, J = 20.9 Hz, 1F, F_p), -152.33 (m, 1F, F_p), -140.19 (dd, J1 = 24.7 Hz, J2 = 6.8 Hz, 1F, F_o), -137.27 (m, 1F, F_o).

Pathway B:



¹H NMR (9:1 CDCl₃/CD₃OD, 298 K) δ -3.77 (d_b, 1H, $\beta\pi^2$), -2.12 (d_b, 1H, $\beta\pi^2$), -2.04 (s, 3H, CH_{3OAc}), 0.89 (m, 1H, CH_{2_BuNH2}), 1.10 (m, 1H, CH_{2_BuNH2}), 1.26 (s, 3H, NMe), 1.43 (m, 1H, CH_{2_BuNH2}), 1.54 (m, 1H, Ar6b), 1.58 (m, 1H, CH_{2_BuNH2}), 1.60 (s, 3H, NMe), 1.91 (s, 3H, NMe), 2.05 (d, J = 11.4 Hz, 1H, ArCH₂), 2.23 (d, J = 11.4 Hz, 1H, ArCH₂), 2.51 (m, 1H, ArCH₂), 2.66 (m, 1H, ArCH₂), 2.83 (d, J = 14.3 Hz, 1H,

ArCH₂), 3.26 (m, 1H, ArCH₂), 3.68 (m, 1H, Ar6c), 4.20 (d_b, 1H, $\beta\pi5$), 4.52 (d_b, 1H, $\beta\pi5$), 5.19 (m, 1H, Ar6d), 6.72 (s, 1H, HAr_{tren}), 6.78 (s, 1H, Ar6a), 6.84 (d_b, J = 6.9 Hz, 1H, HAr_{tren}), 6.88 (d_b, J = 7.7 Hz, 1H, HAr_{meso}), 6.94 (t, J = 7.6 Hz, 1H, HAr_{meso}), 6.97 (t, J = 7.7 Hz, 1H, HAr_{tren}), 7.09-7.22 (m_b, HAr_{meso} + HAr_{tren} + $\beta\pi_{out}$), 7.34-7.55 (m_b, HAr_{meso} + HAr_{tren} + $\beta\pi_{out}$), 7.59 (d, J = 7.6 Hz, 1H, HAr_{meso}), 7.69 (m, 2H, HAr_{meso} + $\beta\pi_{out}$), 7.78 (m, 2H, HAr_{meso}), 8.02 (d, J = 4.8 Hz, 1H, $\beta\pi_{out}$), 8.19 (m, 4H, HAr_{meso}), ¹⁹F NMR (9:1 CDCl₃/CD₃OD, 298 K) δ -162.75 (m, 2F, F_m), -162.45 (m, 2F, F_m), -162.16 (m, 1F, F_m), -160.76 (m, 1F, F_m), -154.18 (t, J = 20.9 Hz, 1F, F_p), -153.44 (m, 2F, F_p), -140.25 (m, 1F, F_o), -139.24 (m, 1F, F_o), -138.27 (dd, J1 = 23.9 Hz, J2 = 8.0 Hz, 1F, F_o), -137.42 (dd, J1 = 24.4 Hz, J2 = 8.3 Hz, 1F, F_o), -135.58 (m, 1F, F_o). UV-visible (9:1 CHCl₃/CH₃OH, λ_{max} nm): 396, 566, 607, 636, 807, 880, 901, 990.

Crystallographic data for 1 [CCDC 1560725]

(C_{45.33}H_{18.67}Cl₄F₁₀N₆O₄); *M* = 1043.13. D8 VENTURE Bruker AXS diffractometer, Mo-Kα radiation (λ = 0.71073 Å), *T* = 150(2) K; Triclinic *P* -1 (I.T.#2), *a* = 14.7140(6), *b* = 15.8048(7), *c* = 17.2717(7) Å, *α* = 78.0620(10), *b* = 69.3740(10), *γ* = 64.0160(10) °, *V* = 3372.5(2) Å³. *Z* = 3, *d* = 1.541 g.cm⁻³, *μ* = 0.356 mm⁻¹. The structure was solved by direct methods using the *SIR97* program,² and then refined with full-matrix least-square methods based on *F*² (*SHELXL-97*).³ The contribution of the disordered solvents to the calculated structure factors was estimated following the *BYPASS* algorithm,⁴ implemented as the *SQUEEZE* option in *PLATON*.⁵ A new data set, free of solvent contribution, was then used in the final refinement. All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. H atoms were finally included in their calculated positions. A final refinement on *F*² with 15413 unique intensities and 869 parameters converged at $\omega R(F^2) = 0.3138$ (*R*(*F*) = 0.1160) for 11260 observed reflections with *I* > 2 σ (*I*).

Crystallographic data for 5 [CCDC 1560726]

(C₈₄H₆₄F₁₅N₁₃O₃); *M* = 1588.48. D8 VENTURE Bruker AXS diffractometer, Mo-Kα radiation (λ = 0.71073 Å), *T* = 150(2) K; monoclinic *P* 2₁/*c* (I.T.#14), *a* = 18.035(2), *b* = 31.918(4), *c* = 16.6641(18) Å, *G* = 112.641(4) °, *V* = 8853.2(17) Å³. *Z* = 4, *d* = 1.192 g.cm⁻³, μ = 0.096 mm⁻¹. The structure was solved by dual-space algorithm using the *SHELXT* program,⁶ and then refined with full-matrix least-square methods based on *F*² (*SHELXL-2014*).⁷ The contribution of the disordered solvents to the structure factors was calculated by the *PLATON* SQUEEZE procedure⁸ and then taken into account in the final *SHELXL-2014<:1>* least-square refinement. All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. H atoms were finally included in their calculated positions. A final refinement on F² with 20275 unique intensities and 1051 parameters converged at ω R(F²) = 0.2874 (R(F) = 0.1062) for 13083 observed reflections with I > 2 σ (I).

Crystallographic data for 8Zn^{OAc}NH2Bu.H⁺,OTf⁻ [CCDC 1560727]

(C₁₀₅H₈₄F₁₅N₁₄O₅Zn, CF₃O₃S, 2(CHCl₃)); M = 2360.03. D8 VENTURE Bruker AXS diffractometer, Mo-K α radiation ($\lambda = 0.71073$ Å), T = 150 K; monoclinic $P \ 2_1/n$ (I.T.#14), a = 14.8223(7), b = 30.7285(17), c = 27.9264(15) Å, 6 = 97.487(2)°, V = 12611.1(11) Å³. Z = 4, d = 1.243 g.cm⁻³, $\mu = 0.419$ mm⁻¹. The structure was solved by dual-space algorithm using the *SHELXT* program,⁶ and then refined with full-matrix least-square methods based on F^2 (*SHELXL-2014*).⁷ The contribution of the disordered solvents to the structure factors was calculated by the *PLATON* SQUEEZE procedure⁸ and then taken into account in the final *SHELXL-2014* least-square refinement. All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. Except nitrogen N₁₅₁ linked hydrogen atom that was introduced in the structural model through Fourier difference maps analysis, H atoms were finally included in their calculated positions. A final refinement on F^2 with 28823 unique intensities and 1363 parameters converged at $\omega R(F^2) = 0.2972$ (R(F) = 0.1208) for 16927 observed reflections with $I > 2\sigma(I)$.



Figure S1. Dihedral angles (°) of $8Zn^{OAc}_{NH2Bu}$. H⁺,OTf⁻ along the SMC.

II. NMR spectral data





Figure S2. VT ¹H NMR spectra of 1.



Figure S3. 2D COSY NMR spectrum (CDCl₃, 330 K) of 1. S = solvent, G = grease.



Figure S4. 2D HSQC NMR spectrum (CDCl₃, 298 K) of 1. S = solvent, W = water.



Figure S5. ¹⁹F NMR spectra (CDCl₃, 298 K) of 1.

Selected NMR spectra of 3 and 6



Figure S6. ¹H NMR spectra (CDCl₃, 298 K) of **3** (a) and **6** (b). S = solvent, G = grease.

Note: the ¹H NMR spectra of **3** and **6** are ill defined at 298 K, likely due to both the fast interconversion between several Möbius conformations and *meso*-aryl atropisomers.



-134 -135 -136 -137 -138 -139 -140 -141 -142 -143 -144 -145 -146 -147 -148 -149 -150 -151 -152 -153 -154 -155 -156 -157 -158 -159 -160 -161 -162 -163 -164 f1 (pom)

Figure S7. $^{19}\mathsf{F}$ NMR spectra (CDCl₃, 298 K) of **3** (a) and **6** (b).



Figure S8. 2D COSY NMR spectrum (CDCl₃, 298 K) of 4. S = solvent, G = grease.



Figure S9. 2D ROESY NMR spectrum (CDCl₃, 298 K) of 4. S = solvent, G = grease.



Figure S10. 2D HSQC NMR spectrum (CDCl₃, 298 K) of 4. S = solvent, G = grease.



Figure S11. ¹⁹F NMR spectrum (CDCl₃, 298 K) of 4.



Figure S12. 2D COSY NMR spectrum (CDCl₃, 298 K) of **5**. S = solvent, G = grease.



Figure S13. 2D HSQC NMR spectrum (CDCl₃, 298 K) of 5. S = solvent, G = grease.



Figure S14. 2D HMBC NMR spectrum (CDCl₃, 298 K) of 5. S = solvent, G = grease.



Figure S15. ¹⁹F NMR spectrum (CDCl₃, 298 K) of **5**.



Figure S16. 2D COSY NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of 9. S = solvent, G = grease, W = water, * = Et_3N .



Figure S17. 2D HSQC NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of 9. S = solvent, G = grease, W = water, * = Et_3N .



Selected NMR spectra of 10

Figure S18. 2D COSY NMR spectrum (CDCl₃, 298 K) of **10**. S = solvent, G = grease.



Figure S19. 2D HSQC NMR spectrum (CDCl₃, 298 K) of 10. S = solvent, G = grease.



Figure S20. 2D HMBC NMR spectrum (CDCl₃, 298 K) of 10. S = solvent, G = grease.



Figure S21. ¹⁹F NMR spectrum (CDCl₃, 298 K) of 10.



Figure S22. 2D COSY NMR spectrum (CDCl₃, 298 K) of 8. S = solvent, G = grease.



Figure S23. 2D HSQC NMR spectrum (CDCl₃, 298 K) of 8. S = solvent, G = grease.



Figure S24. 2D HMBC NMR spectrum (CDCl₃, 298 K) of 8. S = solvent, G = grease.



Figure S25. ¹⁹F NMR spectrum (CDCl₃, 298 K) of **8**.



Figure S26. 2D COSY NMR spectrum (CDCl₃, 298 K) of **11**. S = solvent, G = grease, * = Et₃N.



Figure S27. 2D HSQC NMR spectrum (CDCl₃, 298 K) of **11**. S = solvent, G = grease, $* = Et_3N$.



Figure S28. Comparison of the ¹H NMR spectra (selected parts) of **10** (a) and **11** (b) (CDCl₃, 298 K, 500 MHz). S = solvent; G = grease; "L"/"S" italicized stand for "long"/"short".

Additional comment. Shielding effects are opposite to those observed for the parent 28π compounds: (i) the inner β -pyrrolic protons (-2.9 to -3.2 ppm for **10** and **11**) are located in the highfield region, (ii) the outer β -pyrrolic protons are deshielded (9.0 to 9.6 ppm for **10** and **11**), (iii) the tren CH₂ and NMe protons are markedly upfield shifted (δ_{CH2} down to -2.85 and 0.05 ppm for **10** and **11**; $\delta_{NMe(L)} = -0.47$ and 0.21 ppm for **10** and **11**). Similarly to the parent 28π compounds, the tren cap of **10** lies much closer to the hexaphyrin than that of **11**. An extended conformation of the former, stabilized by intramolecular H-bonds, is also expected.



Figure S29. 2D ROESY NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}_{NH2Bu}.H⁺,OTf**⁻. S = solvent, G = grease, W = water.



Figure S30. 2D TOCSY NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}_{NH2Bu}**.H⁺,**OTf**⁻. S = solvent, G = grease, W = water.



Figure S31. 2D HSQC NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}_{NH2Bu}.H⁺,OTf**⁻. S = solvent, G = grease, W = water.



Figure S32. 2D COSY NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}_{NH2Bu}.H⁺,OTf**⁻. S = solvent, G = grease, W = water.



Figure S33. ¹⁹F NMR spectra (9:1 CDCl₃/CD₃OD, 298 K) of 8Zn^{OAc}_{NH2Bu}.



Figure S34. 2D HSQC NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}_{NH2Bu}**. S = solvent, G = grease, W = water.



Figure S35. 2D ROESY NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}NH2Bu**. S = solvent, G = grease, W = water.



Figure S36. 2D COSY NMR spectrum (9:1 CDCl₃/CD₃OD, 298 K) of **8Zn^{OAc}_{NH2Bu}**. S = solvent, G = grease, W = water.



Figure S37. 2D ROESY NMR spectrum (9:1 $CDCl_3/CD_3OD$, 330 K) of **8Zn^{OAc}_{NH2Bu}**: expanded view on the exchange correlations of the butylamino and acetato ligands.



Figure S38. 2D ROESY NMR spectrum (9:1 $CDCl_3/CD_3OD$, 298 K) of **8Zn^{OAc}_{RNH2}.H⁺,OTf**⁻ (RNH₂ = (S)-MBA): expanded view on the exchange correlations of the MBA ligand.



Figure S39. 2D TOCSY NMR spectrum (9:1 $CDCl_3/CD_3OD$) of (a) $8Zn^{OAc}_{NH2Bu}$. H^+ , OTf^- (298 K) and (b) $8Zn^{OAc}_{NH2Bu}$ (330 K): expanded view on the Ar6 moiety.



Figure S40. ¹H NMR spectra (9:1 CDCl₃/CD₃OD) of "**8Zn**", with different combinations of carboxylato and amino ligands: expanded view on the highfield regions (conditions: Pathway A, Pathway B, or modified conditions [excess of all reactants, see text]).

III. UV-vis-NIR absorption spectra



Figure S41. UV-vis-NIR absorption spectra of compounds 3, 4, 6 and 8 (CH₂Cl₂).



Figure S42. UV-vis-NIR absorption spectra of compounds 5 and 10 (CH₂Cl₂).



Figure S43. UV-vis-NIR absorption spectra for the titration of **8** by a 1:1 mixture of $Zn(OAc)_2$ and $BuNH_2$ (9:1 CHCl₃/CH₃OH, DIPEA). Note: the same final absorption spectrum was obtained with a mixture of $Zn(OTf)_2$ and TBAOAc instead of $Zn(OAc)_2$.



Figure S44. Circular dichroism (a) and UV-vis (b) absorption spectra, recorded at 20 °C in 9:1 CHCl₃/MeOH, of: (i) a solution of **8**, Zn(OTf)₂ and (*R*)-MBA heated 15 min at 50 °C (blue curves); (ii) a solution of **8**, Zn(OTf)₂, (*R*)-MBA and TBAOAc heated 15 min at 50 °C (red curves). Conditions: [**8**] = 50 μ M, 20 equiv. of Zn(OTf)₂, 40 equiv. of (*R*)-MBA, 40 equiv. of TBAOAc. Note: the blue CD spectrum shows a weak "Möbius-type" hexaphyrin signature, likely due to undesired contamination with acetate ions, as attested by the absorption band at 609 nm in the corresponding UV spectra (formation of *P-(R)*-82n^{OAc}_{MBA}[.H⁺,OTf⁻]).



Figure S45. Racemization study for the $M \leftrightarrow P$ twist interconversion in "**8Zn**". Conditions: pathway A, NMR tube solution analyzed by CD and UV-vis spectroscopies (CHCl₃/CH₃OH 9:1).

Procedure: to the 85:15 mixture of [M/P]-(S)-8Zn^{OAc}_{MBA}.H⁺,OTf⁻ was added an excess of an achiral ligand such as butylamine (4 equiv.). The MBA <-> BuNH₂ exchange proceeds instantaneously and quantitatively (deduced from ¹H NMR), leading to the two neutral enantiomers [M/P]-8Zn^{OAc}_{BuNH2}. At room temperature, no change in the CD spectrum was observed, indicating amino ligand exchange without loss of chiral induction. In a second step, decreasing of the intensity of the CD signal with the time was monitored. After 10 min at 80 °C, no CD signal was anymore detected, while the UV-vis spectrum was not affected.

- ³ Sheldrick, G.M. Acta Cryst. **2008**, A64, 112-122.
- ⁴ Sluis, P. v.d.; Spek, A. L. Acta Cryst. **1990**, A46, 194-201.
- ⁵ Spek, A. L. J. Appl. Cryst. **2003**, 36, 7-13.
- ⁶ Sheldrick, G.M. Acta Cryst. **2015**, A71, 3-8.
- ⁷ Sheldrick, G.M. *Acta Cryst.* **2015**, *C71*, 3-8.
- ⁸ Spek, A. L. Acta Cryst. **2015**, C71, 9-18.

¹ Littler, B. J.; Miller, M. A.; Hung, C.-H.; Wagner, R. W.; O'Shea, D. F.; Boyle, P. D.; Lindsey, J. S. *J. Org. Chem.* **1999**, *64*, 1391-1396.

² Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R. *J. Appl. Cryst.* **1999**, *32*, 115-119.